What is CEL-SCI?
Founded in 1983 and headquartered in Vienna, Virginia, CEL-SCI is dedicated to the research and development of groundbreaking immunotherapy products. The company's pipeline targets a range of challenging conditions, including cancer, autoimmune disorders, and infectious diseases. This focus positions CEL-SCI at the forefront of innovative therapeutic approaches within the biopharmaceutical sector, aiming to address unmet medical needs through advanced biological interventions.
How much funding has CEL-SCI raised?
CEL-SCI has raised a total of $53.5M across 2 funding rounds:
Stock Offering
$14.7M
Stock Offering
$31.7M
Stock Issuance/Offering (2020): $14.7M with participation from Undisclosed
Stock Issuance/Offering (2021): $31.7M, investors not publicly disclosed
What's next for CEL-SCI?
The recent major strategic investment signals a pivotal moment for CEL-SCI, likely enabling the acceleration of its clinical trial programs and the expansion of its research initiatives. This influx of capital is expected to fuel the company's growth trajectory, potentially paving the way for further development and commercialization of its immunotherapy candidates. The enterprise-level funding context suggests CEL-SCI is in a critical scaling phase, poised to make significant advancements in its therapeutic offerings.
See full CEL-SCI company page
